Ins ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has received IND clearance from FDA for ISM5939, a potential best-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback